Real-World Efficacy of Belimumab in childhood-onset systemic lupus erythematosus: A Retrospective Cohort Analysis Using Propensity Score Matching

Abstract Objective This single-center real-world study aimed to evaluate the efficacy of belimumab in childhood-onset systemic lupus erythematosus (cSLE) and to explore baseline-dependent therapeutic benefits using multivariate logistic regression and propensity score matching (PSM) for mutual validation. Methods A total of 230 cSLE patients (100 receiving belimumab plus conventional therapy and 130 receiving conventional therapy alone) enrolled from June 2020 to May 2025 were analyzed. Nested logistic regression models were constructed based on SRI-4 response at weeks 24 and 54. After 1:1 PSM, 56 matched pairs were included for comparative analysis of laboratory parameters, disease activity scores, and glucocorticoid dosage. Results In the overall cohort, multivariate logistic regression showed that belimumab was independently associated with ≥ 4‑point improvement in SLEDAI‑2K at week 24 (OR = 2.359, 95%CI: 1.114–5.366, P = 0.032) and week 54 (OR = 4.302, 95%CI: 1.703–13.175, P = 0.005). However, these associations became non‑significant after adjustment for baseline SLEDAI‑2K (week 24: OR = 0.608, P = 0.418; week 54: OR = 1.692, P = 0.430). After 1:1 PSM, the belimumab group exhibited significantly higher platelet counts and complement C3 levels, along with lower erythrocyte sedimentation rate (ESR) and anti‑dsDNA antibody titers at week 24. At week 54, the belimumab group achieved superior improvements in hemoglobin, platelet count, ESR, anti‑dsDNA titers, complement C3, and Physician Global Assessment (PGA) scores (all P < 0.05). Conclusion This single‑center real‑world study demonstrates that belimumab effectively improves immunological and hematological parameters and reduces disease activity in cSLE, with a favorable safety profile. The benefits are particularly prominent in hematological domains.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11607816/v1
Primary Topic
Systemic Lupus Erythematosus Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Real-World Efficacy of Belimumab in childhood-onset systemic lupus erythematosus: A Retrospective Cohort Analysis Using Propensity Score Matching

Lili Liu, Jiaran Wang, Zhen Yu, Huasu zhu et al.
4 links
Research Square
Systemic Lupus Erythematosus Research
preprint

Real-World Efficacy of Belimumab in childhood-onset systemic lupus erythematosus: A Retrospective Cohort Analysis Using Propensity Score Matching

Lili Liu, Jiaran Wang, Zhen Yu, Huasu zhu, Yu wang
preprint en

Abstract

Abstract Objective This single-center real-world study aimed to evaluate the efficacy of belimumab in childhood-onset systemic lupus erythematosus (cSLE) and to explore baseline-dependent therapeutic benefits using multivariate logistic regression and propensity score matching (PSM) for mutual validation. Methods A total of 230 cSLE patients (100 receiving belimumab plus conventional therapy and 130 receiving conventional therapy alone) enrolled from June 2020 to May 2025 were analyzed. Nested logistic regression models were constructed based on SRI-4 response at weeks 24 and 54. After 1:1 PSM, 56 matched pairs were included for comparative analysis of laboratory parameters, disease activity scores, and glucocorticoid dosage. Results In the overall cohort, multivariate logistic regression showed that belimumab was independently associated with ≥ 4‑point improvement in SLEDAI‑2K at week 24 (OR = 2.359, 95%CI: 1.114–5.366, P = 0.032) and week 54 (OR = 4.302, 95%CI: 1.703–13.175, P = 0.005). However, these associations became non‑significant after adjustment for baseline SLEDAI‑2K (week 24: OR = 0.608, P = 0.418; week 54: OR = 1.692, P = 0.430). After 1:1 PSM, the belimumab group exhibited significantly higher platelet counts and complement C3 levels, along with lower erythrocyte sedimentation rate (ESR) and anti‑dsDNA antibody titers at week 24. At week 54, the belimumab group achieved superior improvements in hemoglobin, platelet count, ESR, anti‑dsDNA titers, complement C3, and Physician Global Assessment (PGA) scores (all P < 0.05). Conclusion This single‑center real‑world study demonstrates that belimumab effectively improves immunological and hematological parameters and reduces disease activity in cSLE, with a favorable safety profile. The benefits are particularly prominent in hematological domains.

Research Square
Qilu Hospital of Shandong University (CN)
Good health and well-being
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon